REGULATORY

• Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
  March 22, 2024

• New LDP Project Team Launched to Boost Global Access to Infectious Disease Drugs
  March 21, 2024

• Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
  March 19, 2024

• Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
  March 19, 2024

• Japan to Work towards Ensuring Consistency in Different Clinical Trial Laws
  March 19, 2024

• Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
  March 19, 2024

• Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
  March 18, 2024

• Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
  March 18, 2024

• Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
  March 15, 2024

• Japan Begins Discussions on RSV Vaccines for National Immunization Program
  March 15, 2024

• Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
  March 15, 2024

• Xocova Set for Renewed Price-Setting after Full Approval, Big Cut Unlikely
  March 14, 2024

• PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
  March 14, 2024

• CellCept, Paraplatin Now Eligible for Health Coverage
  March 14, 2024

• LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
  March 14, 2024

• Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
  March 14, 2024

• Disclosure Guidelines on Generic Supply Info Up for Public Comments
  March 13, 2024

• Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
  March 13, 2024

• English Versions of MHLW Biosimilar Trial Guidance, Q&As Now Available
  March 13, 2024

• Japan to Simplify Screening for Third-Party Use of Highly Anonymous NDB Data
  March 11, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• …
• Next ›
• 最終 »